编号：2018-11-29-1 证券代码：300391 证券简称：康跃科技 康跃科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |--------------|------------------------------|--------------------------------------------------------------| | | | | | 投资者关系活 | √ | 特定对象调研 □分析师会议 | | 动类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | 参与单位名称 | 财通证券股份有限公司：龚斯闻 | | | 及人员姓名 | | 国泰君安证券股份有限公司：石金漫 | | | 招商证券股份有限公司：普绍增 | | | | | 中银国际证券股份有限公司：李可伦 | | 时间 | 2108 年 11 月 | 29 日 14:00-17:00 | | 地点 | 山东寿光经济开发区洛前街 | 1 号公司会议室 | | 上市公司接待 | 总 ...

Group 1: Company Overview - Kangyue Technology Co., Ltd. was listed on the Growth Enterprise Market in August 2014 and acquired Hebei Yihang Technology Co., Ltd. in 2017 [2] - The company's business segments are primarily divided into three parts: photovoltaic equipment, photovoltaic modules, and booster products [2] Group 2: Revenue Distribution - In the first three quarters of 2018, the revenue distribution among business segments was approximately: booster segment accounted for around 40%, while photovoltaic equipment and photovoltaic modules each accounted for around 30% [3] Group 3: Photovoltaic Business Insights - The wholly-owned subsidiary Yihang Technology focuses on the R&D, production, and sales of key equipment for intelligent photovoltaic module production lines [3] - Global photovoltaic module installation is expected to grow to 130 GW in 2019, with leading manufacturers adding over 20 GW of new capacity [3] - The company’s core equipment products for photovoltaic module production lines can meet customer demands for equipment upgrades and replacements [3] Group 4: Competitive Advantages - Yihang Technology has developed leading automation and electromechanical integration technologies, enabling rapid customer response and maintaining a competitive edge in product innovation [4] - The company continuously strengthens its R&D team to enhance product innovation and maintain the ability to introduce new products to the market [4] Group 5: Booster Products - The company’s turbocharger products have expanded from commercial vehicles and engineering machinery to large turbochargers since 2016, adapting to stricter emission standards [4]

证券代码：300391 证券简称：康跃科技 康跃科技股份有限公司投资者关系活动记录表 编号：2022-05-06-1 | --- | --- | --- | |-------------------------|----------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活 | □特定对象调研 | □分析师会议 | | 动类别 | □媒体采访 √业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | （请文 ...

康跃科技股份有限公司 2022 年第三季度报告 证券代码：300391 证券简称：康跃科技 公告编号：2022-105 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 康跃科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 1 康跃科技股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 430,797,479.50 | -17.26% | 1,422,647,907.32 | -21.76% | | 归属于上市公司股东 | 67,700,721.70 | 432.85% | 27,425,057.22 | ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 500 million RMB for the first half of 2022, representing a 20% growth compared to the same period last year[15]. - The company's operating revenue for the reporting period was ¥991,850,427.82, a decrease of 23.56% compared to ¥1,297,636,956.91 in the same period last year[23]. - The net profit attributable to shareholders was -¥40,275,664.48, representing a decline of 147.95% from ¥83,994,308.73 in the previous year[23]. - The total revenue for the reporting period was 991.85 million yuan, a decrease of 23.56% year-on-year, with a net profit attributable to shareholders of -40.28 million yuan, a decline of 147.95%[41]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the first half of 2022, representing a year-over-year growth of 25%[113]. - The company reported a total operating revenue of 991.85 million yuan, a decrease of 23.56% year-on-year, and a net profit attributable to shareholders of -40.28 million yuan, a decline of 147.95% compared to the previous year[84]. User Growth - User data indicates a growth in active users, reaching 1.2 million, which is a 15% increase year-over-year[15]. - User data showed a total of 10 million active users by the end of June 2022, an increase of 15% compared to the previous year[123]. - The company has a strong marketing system and has established a solid customer base in the internal combustion engine parts market[37]. Future Outlook - The company has provided a positive outlook for the second half of 2022, projecting a revenue growth of 25%[15]. - The company provided a positive outlook for the second half of 2022, projecting a revenue growth of 20% to 30% based on current market trends and user acquisition strategies[122]. - The company plans to expand its main business to include traditional Chinese medicine, hollow capsules, and pharmaceutical wholesale after a major asset restructuring[88]. - The company plans to control shipments to manage accounts receivable and reduce channel inventory in response to market conditions[85]. Product Development - New product development includes the launch of a cutting-edge technology platform aimed at enhancing user experience, expected to be fully operational by Q4 2022[15]. - New product launches are expected to contribute an additional 200 million in revenue by the end of 2022[113]. - The company has developed a series of capsule formulations to address quality demands, including anti-fracture formulations for traditional Chinese medicine capsules[44]. Market Expansion - The company is expanding its market presence by entering two new regions, which is anticipated to contribute an additional 50 million RMB in revenue[15]. - Market expansion plans include entering three new international markets by Q4 2022, aiming for a 10% market share in each[113]. - The company is actively engaged in the research and development of fuel cell electronic control turbochargers, with prototypes and performance tests recognized by clients[37]. Financial Health - The total assets of the company have increased to 1.2 billion RMB, reflecting a 10% growth from the previous year[15]. - The company's total assets reached CNY 4,279,123,989.68, up from CNY 4,214,473,787.82, reflecting an increase of about 1.5%[176]. - The company's equity attributable to shareholders decreased to CNY 786,060,645.51 from CNY 826,282,705.59, a decline of about 4.9%[176]. Research and Development - The company plans to invest 100 million RMB in research and development for new technologies over the next year[15]. - The company is investing heavily in R&D, with a budget increase of 30% for new technology development[113]. - The company has a specialized R&D team of nearly 100 people focused on core turbocharger technology innovation[52]. Risk Management - The company has identified potential risks including market competition and regulatory changes, with strategies in place to mitigate these risks[3]. - The company is closely monitoring the operating conditions of its subsidiaries to mitigate the risk of goodwill impairment following the acquisition[89]. Compliance and Governance - The company has committed to maintaining independence and compliance with relevant laws and regulations following the completion of its asset restructuring[118]. - The company has assured that it has not provided any external guarantees or allowed its funds to be used improperly by controlling entities[119]. - The company has pledged to uphold the rights and interests of its investors, committing to ethical business practices[119]. Shareholder Relations - No cash dividends or stock bonuses will be distributed to shareholders for this period, as the company focuses on reinvestment[4]. - The company has established a decision-making and operational structure involving the shareholders' meeting, board of directors, supervisory board, and management to protect shareholders' rights[102]. - The company has engaged with investors through various channels to improve understanding and communication[103].

Financial Performance - The company's revenue for Q1 2022 was ¥545,403,773.14, a decrease of 30.53% compared to ¥785,147,049.48 in the same period last year[3] - Net profit attributable to shareholders was ¥14,645,911.14, down 75.35% from ¥59,407,361.17 year-on-year[3] - Total operating revenue for Q1 2022 was ¥545,403,773.14, a decrease of 30.6% compared to ¥785,147,049.48 in Q1 2021[16] - Net profit for Q1 2022 was ¥50,233,749.76, a decline of 52.8% from ¥106,260,897.63 in Q1 2021[17] - The net profit attributable to the parent company for Q1 2022 was ¥14,645,911.14, down 75.4% from ¥59,407,361.17 in Q1 2021[17] - The company reported a total comprehensive income of ¥50,190,853.23 for Q1 2022, down from ¥106,268,532.66 in the same period last year[17] Cash Flow - The net cash flow from operating activities was -¥41,839,544.89, a decline of 15.98% compared to -¥36,074,307.49 in the previous year[3] - Total cash inflow from operating activities was 496,174,234.37 CNY, down 36.0% from 774,178,788.15 CNY in the previous period[19] - Cash outflow from operating activities totaled 538,013,779.26 CNY, a decrease of 33.5% from 810,253,095.64 CNY in the previous period[19] - The net cash flow from investing activities was -58,158,351.82 CNY, worsening from -21,671,475.69 CNY in the previous period[20] - Cash inflow from financing activities was 451,762,000.00 CNY, an increase of 130.5% compared to 195,697,783.47 CNY in the previous period[20] - The net cash flow from financing activities improved to 194,088,746.52 CNY, compared to 8,179,398.42 CNY in the previous period[20] - The ending balance of cash and cash equivalents was 176,334,344.55 CNY, significantly up from 57,385,275.97 CNY in the previous period[20] - Cash received from the acquisition of loans was 408,012,000.00 CNY, compared to 169,980,000.00 CNY in the previous period, reflecting increased borrowing[20] - Cash paid for debt repayment was 245,753,032.67 CNY, an increase from 179,917,561.10 CNY in the previous period[20] Assets and Liabilities - Total assets increased by 3.81% to ¥4,375,196,841.05 from ¥4,214,473,787.82 at the end of the previous year[3] - Total liabilities as of Q1 2022 amounted to ¥2,715,869,616.76, an increase from ¥2,605,178,650.74 in the previous year[14] - Total equity attributable to shareholders of the parent company was ¥840,726,954.19, up from ¥826,282,705.59 in Q1 2021[14] - The company reported a total of 2,251,440,637.09 in current assets, up from 2,058,953,930.43, which is an increase of about 9.3%[13] - The company’s total current liabilities were ¥2,162,228,607.80, slightly up from ¥2,109,917,350.56 in Q1 2021[14] Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,980[9] - The largest shareholder, Changxing Shengshi Fenghua Business Co., Ltd., holds 18.81% of shares, totaling 65,897,500 shares[9] Operational Metrics - The weighted average return on equity decreased to 1.76% from 7.37% year-on-year, a drop of 5.61%[3] - Research and development expenses for Q1 2022 were ¥8,157,597.25, a decrease from ¥10,940,213.27 in Q1 2021[16] - Total operating costs for Q1 2022 were ¥482,568,751.14, down 29.4% from ¥683,016,461.70 in the same period last year[16] - Basic and diluted earnings per share for Q1 2022 were both ¥0.0418, a decrease from ¥0.1696 in Q1 2021[18] Inventory and Receivables - Accounts receivable rose to ¥1,433,465,607.14 from ¥1,377,957,524.35, indicating an increase of about 4.0%[12] - Inventory decreased to ¥159,065,948.60 from ¥195,347,478.13, showing a decline of approximately 18.5%[13] Product Development and Mergers - The company did not report any new product developments or market expansion strategies during this quarter[3] - The company has not disclosed any new product or technology developments in the current report[10] - There are no significant mergers or acquisitions reported during the period[10] Audit Information - The company did not undergo an audit for the first quarter report[21]

Financial Performance - The company's operating revenue for 2021 was ¥2,361,946,450.06, representing a 94.48% increase compared to ¥1,214,503,960.24 in 2020[27]. - The net profit attributable to shareholders for 2021 was ¥49,104,524.78, a 93.94% increase from ¥25,319,988.66 in 2020[27]. - The net cash flow from operating activities reached ¥230,987,890.32, marking a significant increase of 604.11% from ¥32,805,640.00 in 2020[27]. - The basic earnings per share for 2021 was ¥0.1402, up 93.91% from ¥0.0723 in 2020[27]. - The company achieved a total revenue of CNY 2,361.95 million in 2021, representing a year-on-year growth of 94.48%[63]. - The pharmaceutical manufacturing segment generated revenue of CNY 1,558.35 million, a significant increase of 433% compared to the previous year[64]. - The company’s net profit for the reporting period was CNY 49.10 million, up 93.94% from the previous year[63]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB, representing a year-over-year growth of 25%[175]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 20% to 1.8 billion RMB[179]. Accounts Receivable and Cash Flow - As of the end of the reporting period, accounts receivable amounted to RMB 1,377.96 million, accounting for 66.93% of current assets, indicating potential pressure on cash flow and working capital[6]. - The company aims to strengthen accounts receivable management by establishing a sales collection assessment mechanism to control the scale of accounts receivable[7]. - The company reported a significant increase in accounts receivable, which rose to ¥1,377,957,524.35, representing 32.70% of total assets, up from 25.43% in the previous year[97]. - The net increase in cash and cash equivalents was -¥24,425,776.85, an improvement of 84.13% from -¥153,893,763.91 in 2020, due to increased cash flow from operating and financing activities[92]. Strategic Goals and Commitments - The company has committed to achieving a net profit of no less than RMB 180 million for 2020 and RMB 200 million for 2021, with a cumulative target of RMB 610 million for 2020-2022, highlighting performance expectations amid market uncertainties[9]. - The company is focusing on expanding its cooperation with hospitals and increasing the variety of products sold in the pharmaceutical distribution sector[112]. - The company plans to enhance its management capabilities and integrate new pharmaceutical-related businesses, including traditional Chinese medicine and pharmaceutical wholesale, following a significant asset restructuring[8]. - The company is committed to enhancing operational efficiency and reducing costs through improved management practices[5]. Market Development and Innovation - The company is increasing efforts in market development and technological innovation to improve product competitiveness and profitability[5]. - The company is actively expanding its market share in the turbocharger sector by accelerating product technology upgrades and quality improvements[39]. - The company is focusing on integrating advanced production technologies and diversifying sales channels in the pharmaceutical excipients sector[107]. - The company is developing a traditional Chinese medicine formula aimed at treating viral pneumonia and influenza, with a clinical research success rate of over 95%[87]. Risks and Challenges - The company faces risks related to goodwill impairment due to the acquisition of new businesses, which may affect future operating performance if expectations are not met[11]. - The company acknowledges risks associated with macroeconomic fluctuations and industry policy changes that could impact product demand and operational stability[5]. - The company faces risks related to industry policies, accounts receivable, and potential goodwill impairment following its major asset restructuring[115]. Governance and Compliance - The company has established a transparent performance evaluation and incentive mechanism for its directors and senior management[121]. - The company strictly adheres to relevant laws and regulations, enhancing corporate governance and internal control systems[120]. - The company has not faced any regulatory criticism regarding information disclosure during the reporting period[122]. - The company has implemented a registration management system for insider information, ensuring strict control over information disclosure[123]. Research and Development - The company has a professional R&D team focused on core turbocharger technologies, enhancing its competitive position in the internal combustion engine parts industry[44]. - The R&D investment in 2021 was ¥39,363,616.29, down from ¥43,155,449.34 in 2020, reflecting a trend of reduced investment in R&D[88]. - Research and development investments have increased by 30%, focusing on advanced technology in the pharmaceutical sector[179]. Environmental and Social Responsibility - The company has implemented measures to strictly control environmental pollution and comply with national environmental protection laws[159]. - The company actively fulfills corporate social responsibility, adhering to laws and regulations, and has contributed to local pandemic prevention efforts, including donating masks and medical supplies worth 260,000 RMB[162]. Employee and Management Structure - The total number of employees at the end of the reporting period was 1,581, with 1,576 from major subsidiaries and 5 from the parent company[145]. - The company has a performance assessment and incentive system for senior management remuneration[138]. - The management team includes professionals with backgrounds in finance, engineering, and pharmaceuticals[135].

Financial Performance - The company's revenue for Q3 2021 reached ¥520,639,780.76, representing an increase of 88.36% compared to the same period last year[3]. - Net profit attributable to shareholders was ¥12,705,374.70, up 54.47% year-on-year, while the net profit after deducting non-recurring gains and losses was ¥7,533,729.99, an increase of 68.34%[3]. - Year-to-date revenue reached ¥1,818,276,737.67, reflecting a significant growth of 181.86% compared to the previous year[3]. - The company experienced a 181.86% increase in operating income primarily due to the acquisition of Changjiang Star in December 2020[8]. - Total operating revenue for the third quarter reached ¥1,818,276,737.67, a significant increase from ¥645,101,554.54 in the same period last year, representing a growth of approximately 181.5%[21]. - Net profit for the quarter was ¥190,605,005.24, a substantial rise from ¥140,209.88 year-over-year, reflecting a growth of approximately 135,500%[22]. - Earnings per share (EPS) for the quarter was ¥0.2760, compared to ¥0.0025 in the same quarter last year, marking an increase of 10,840%[23]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period was ¥185,215,404.74, showing a remarkable increase of 1,321.92%[3]. - Cash flow from operating activities was ¥1,480,917,576.25, significantly higher than ¥412,197,888.64 in the previous year, showing an increase of about 259.5%[25]. - The net cash flow from operating activities for Q3 2021 was ¥185,215,404.74, a significant improvement compared to a net outflow of ¥15,157,777.17 in Q3 2020[26]. - Total cash inflow from investment activities was ¥533,399,869.51, while cash outflow was ¥819,481,595.70, resulting in a net cash flow of -¥286,081,726.19 for the quarter[26]. - Cash inflow from financing activities totaled ¥601,714,504.83, with a net cash flow of ¥82,771,146.89 after outflows[27]. - The company reported a total cash and cash equivalents balance of ¥88,775,727.37 at the end of Q3 2021, down from ¥106,892,283.87 at the beginning of the quarter[27]. - The company received ¥362,580,000.00 in cash from borrowings during the quarter, compared to ¥115,700,000.00 in the same period last year[27]. - Cash received from other financing activities amounted to ¥239,134,504.83, an increase from ¥49,878,674.25 year-over-year[27]. - The company paid ¥480,463,386.53 in debt repayments during Q3 2021, compared to ¥185,000,000.00 in Q3 2020[27]. - The total cash outflow for operating activities was ¥1,368,183,908.26, compared to ¥455,574,533.80 in the previous year[26]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥4,279,064,810.47, a decrease of 8.63% from the end of the previous year[3]. - The company's current assets totaled approximately RMB 2.23 billion, compared to RMB 2.12 billion at the end of 2020, indicating an increase of about 5.2%[17]. - The total liabilities decreased from ¥3,233,554,499.76 to ¥2,638,239,341.32, a reduction of approximately 18.4%[22]. - The total equity attributable to shareholders of the parent company increased from ¥776,694,642.74 to ¥874,133,348.55, reflecting a growth of about 12.5%[22]. - The company reported a total current liability of approximately RMB 2.14 billion, down from RMB 2.63 billion, indicating a decrease of about 18.4%[18]. - The non-current assets totaled approximately RMB 2.05 billion, down from RMB 2.56 billion, indicating a decrease of about 20.0%[18]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 8,185[10]. - The company completed the acquisition of a 52.7535% stake in Hubei Changjiang Star Pharmaceutical Co., with a total transaction value of approximately RMB 1.41 billion[15]. - The company plans to raise up to RMB 140 million through a simplified procedure for issuing shares to specific targets[15]. Operational Changes - The construction site for the pharmaceutical research and development center has been changed from Shenzhen to Gong'an County, Hubei Province[15]. - The company reported a significant increase in accounts receivable financing by 50.57% due to an increase in receivables[8]. - The company recorded a 465.39% increase in asset disposal gains, amounting to ¥3,147,878.67, due to the disposal of properties and land[9]. Other Financial Metrics - The weighted average return on equity was 1.46% for the current period, compared to 1.09% in the same period last year[3]. - The company reported a credit impairment loss of ¥-37,317,188.90, compared to ¥-2,012,163.15 in the previous year, indicating a deterioration in credit quality[22]. - The company’s deferred income tax liabilities decreased from ¥10,946,186.91 to ¥9,248,506.31, a decline of approximately 15.5%[22]. - The total comprehensive income for the quarter was ¥190,597,398.24, compared to a loss of ¥-5,681,553.49 in the same quarter last year, indicating a significant turnaround[23]. Audit and Compliance - The company did not undergo an audit for the Q3 2021 report[28]. - The report indicates that the company has not applied the new leasing standards for the current year[28].

Financial Performance - The company's operating revenue for the reporting period reached CNY 1,297,636,956.91, representing a 251.95% increase compared to CNY 368,695,236.50 in the same period last year[22]. - Net profit attributable to shareholders was CNY 83,994,308.73, a significant increase of 1,241.34% from a loss of CNY 7,359,246.27 in the previous year[22]. - The net profit after deducting non-recurring gains and losses was CNY 77,160,407.76, up 689.94% from a loss of CNY 13,079,424.81 in the same period last year[22]. - The net cash flow from operating activities was CNY 38,266,174.48, a turnaround from a negative cash flow of CNY 35,008,631.60, marking a 209.30% increase[22]. - Basic earnings per share increased to CNY 0.2398 from a loss of CNY 0.0210, reflecting a 1,241.90% improvement[22]. - The company achieved a revenue of 1,297.64 million CNY, representing a year-on-year growth of 251.95%, and a net profit of 83.99 million CNY, up 1,241.34% compared to the same period last year[37]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan for the first half of 2021, representing a year-over-year growth of 25%[95]. - The company reported a significant increase in revenue, achieving a total of 500 million yuan for the first half of 2021, representing a 20% year-over-year growth[111]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,317,878,266.79, a decrease of 7.80% from CNY 4,683,035,941.29 at the end of the previous year[22]. - The total liabilities stood at CNY 2,289,900,916.16, reflecting a significant portion of the total assets[161]. - The total liabilities as of June 30, 2021, amounted to CNY 2,708,853,113.60, down from CNY 3,233,554,499.76 at the end of 2020, reflecting a decrease of approximately 16.2%[163]. - The total equity attributable to shareholders of the parent company increased to CNY 861,643,974.34 from CNY 776,694,642.74 at the end of 2020, an increase of about 10.9%[163]. Operational Efficiency - The company operates 8 fully automated production lines and 20 semi-automated lines, with a total capacity exceeding 17 billion capsules[41]. - The fully automated production lines have a capsule filling success rate of ≥99.99% and a product quality rate of ≥99.0%, compared to the semi-automated lines with rates of ≥99.0% and ≥97.0% respectively[42]. - The company has implemented strict quality control measures from raw material procurement to production, ensuring compliance with GMP standards and maintaining a good market reputation[44]. - The gross profit margin for turbochargers was 26.09%, while for photovoltaic equipment it was 15.41%, indicating a slight increase in profitability for turbochargers compared to the previous year[55]. Market and Product Development - The pharmaceutical manufacturing sector is the company's main business, with a focus on traditional Chinese medicine and related products, benefiting from increasing market demand driven by healthcare reforms and rising disposable income[29]. - The company is actively developing a fuel cell electric control turbocharger, currently in the prototype testing phase, to enhance its product offerings in the internal combustion engine sector[33]. - The company specializes in the production of fully automatic laminators and welding machines for solar photovoltaic components, which are essential for production lines[36]. - The company aims to expand its market share in the turbocharger sector by leveraging technological innovations and quality improvements[33]. - The company has developed optimized capsule formulations to address issues such as fragility and cross-linking reactions, enhancing product quality and effectiveness[39]. - The company has established a complete production chain for traditional Chinese medicine, enhancing its competitive advantage in the pharmaceutical industry[30]. - The company has developed advanced turbocharger products, with several recognized as national key new products, showcasing its technological leadership[48]. - The company has developed a range of intelligent equipment for the photovoltaic industry, filling gaps in domestic automation and intelligence in component packaging equipment[50]. Corporate Governance and Compliance - The company has a robust internal control system and governance structure to maximize shareholder value while ensuring creditor interests[87]. - The company is committed to not engaging in any business that competes with its own operations, ensuring compliance with competition regulations[91]. - The management emphasized the importance of maintaining financial independence and robust governance structures to support sustainable growth[95]. - The company has committed to transparency in its financial dealings, ensuring that all related party transactions are conducted at fair market value[111]. - The company has maintained a strong commitment to compliance, with no instances of non-compliance or regulatory issues reported[117]. Risks and Challenges - The company faces several risks, including industry policy risks and financial risks, which are detailed in the report[5]. - The company faces risks related to industry policies, financial management, and business expansion, particularly following the acquisition of Changjiang Star, which diversifies into the pharmaceutical sector[75]. - The company has not reported any significant legal issues or penalties affecting the company during the reporting period, ensuring a stable operational environment[116]. Research and Development - Research and development expenses slightly decreased by 3.20% to ¥19,005,839.36 from ¥19,634,002.78[53]. - The company has a specialized R&D team of nearly 100 people, leading the industry in patent applications and technological innovation[48]. - The company is investing heavily in R&D, with a budget increase of 30% to enhance technology development[99]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares[6]. - The annual shareholders' meeting had a participation rate of 32.47% on May 19, 2021[79]. - The largest shareholder, Shenzhen Shengshi Fenghua Enterprise Management Co., Ltd., held 29.90% of the shares, totaling 104,750,500 shares[145].

Financial Performance - The company's operating revenue for 2020 was CNY 1,214,503,960.24, representing a 67.45% increase compared to CNY 725,310,882.76 in 2019[29]. - The net profit attributable to shareholders for 2020 was CNY 25,319,988.66, a significant turnaround from a loss of CNY 669,698,127.69 in 2019, marking a 103.78% improvement[29]. - The net cash flow from operating activities increased by 47.10% to CNY 32,805,640.00 in 2020, compared to CNY 22,302,178.44 in 2019[29]. - The total assets of the company reached CNY 4,683,035,941.29 by the end of 2020, a 207.46% increase from CNY 1,523,130,740.93 at the end of 2019[29]. - The basic earnings per share for 2020 was CNY 0.0723, recovering from a loss of CNY 1.9116 per share in 2019, reflecting a 103.78% improvement[29]. - The company reported a weighted average return on equity of 3.32% in 2020, a significant recovery from -61.13% in 2019, indicating improved profitability[29]. - The company achieved total operating revenue of 1,214.50 million yuan, an increase of 67.45% compared to the same period last year[61]. - The net profit attributable to the parent company was 25.32 million yuan, marking a turnaround from losses, primarily due to increased sales in internal combustion engine parts and photovoltaic equipment[61]. Strategic Goals and Commitments - The company has committed to achieving a net profit of no less than CNY 180 million for 2020, and CNY 200 million for 2021, with a cumulative target of CNY 610 million for 2020-2022[12]. - The company plans to enhance management capabilities and market development to meet performance commitments amid potential economic fluctuations and competition[12]. - The company emphasizes financial trust and regular reporting from subsidiaries to monitor operational status and achieve performance targets[12]. - The company has set performance commitments for the acquired assets, with net profits for 2020 and 2021 not to be less than RMB 180 million and RMB 200 million respectively, and a cumulative target of RMB 610 million over three years[129]. Market and Industry Trends - The internal combustion engine industry achieved a total revenue of 434.45 billion yuan in 2020, with a year-on-year growth of 13.81%[38]. - The total profit of the internal combustion engine industry reached 39.39 billion yuan in 2020, reflecting a year-on-year increase of 7.15%[38]. - The company’s pharmaceutical segment is positioned to benefit from the increasing demand for traditional Chinese medicine, especially during the COVID-19 pandemic[43]. - The demand for traditional Chinese medicine (TCM) has increased significantly due to its effectiveness in alleviating symptoms during the COVID-19 pandemic, leading to a historical development opportunity for the TCM industry[114]. - The Chinese herbal medicine industry is projected to maintain an annual growth rate of approximately 15% from 2018 to 2023, with sales expected to exceed 500 billion yuan by 2023[111]. Operational Challenges and Risks - The company faces risks related to industry policy changes and economic cycles that could impact product demand and operational performance[6]. - The company faces risks related to macroeconomic fluctuations and changes in national industrial policies, which could affect product demand and operational performance[127]. - The company has not distributed cash dividends or increased capital stock in the past three years, focusing on maintaining business stability[134]. Research and Development - The company is committed to improving product performance through technological innovation to enhance competitiveness and profitability[6]. - The company has a professional R&D team of nearly 100 people, leading the industry in the number of patent applications and having received multiple awards for technological innovation[56]. - The company is actively exploring new markets and optimizing production processes to enhance competitiveness in the pharmaceutical wholesale sector[67]. - The company plans to continue its focus on research and development in new energy fuel cell electric turbochargers and micro electric compressors for the home appliance industry[62]. Asset Management and Restructuring - Significant changes in major assets occurred due to the acquisition of Changjiang Star, impacting fixed assets, intangible assets, and construction in progress[46]. - The overall impact of the major asset restructuring involving Changjiang Star is expected to significantly boost the company's pharmaceutical business[109]. - The company completed the acquisition of 52.75% of Changjiang Star Pharmaceutical Co., with an investment of 93,302 million RMB, enhancing its pharmaceutical manufacturing business[102]. Corporate Governance and Compliance - The company has established measures to regulate potential related party transactions to ensure fairness and compliance with market standards[137]. - The company is committed to maintaining transparency and integrity in its financial dealings and related party transactions[137]. - The actual controller and shareholders have fulfilled their commitments during the reporting period, with no violations reported[136]. - The company has not reported any cash dividends for the years 2019 and 2020, indicating a focus on reinvestment or other financial strategies[135]. Customer and Market Engagement - The company aims to strengthen customer demand management and optimize product structure to maintain reasonable inventory levels[9]. - The company’s marketing strategy focuses on customer-centric value creation, leading to a strong reputation and recognition among pharmaceutical enterprises[55]. - The company is enhancing its governance structure and internal control systems to improve risk resistance and core competitiveness[127].